Objective: The aim of this study was to assess the potential drug-drug interactions (pDDIs) among hospitalized patients in cardiac department in tertiary care hospital. Methods: A prospective, observational study was carried out for a period of 6 months. Samples of 425 patients were assessed for pDDIs using Micromedex®- 2.7. Results: A total of 425 patients were analysed during these study periods. Out of 425 cardiac patients, 360 (84.70%) had found to be pDDIs, 856 pDDIs were found in 360 cardiac patients. With potential drug-drug interactions (pDDIs) higher in male [252 (70.00%)]patients, compared to females. Incidences of pDDIs were found to be higher in the age group of 60-70 years in cardiac [159 (44.16%)] patients and incidences of interactions based on duration of 4-6 days hospital stays in cardiac were 251 (69.72%). Moreover, 51.66% cardiac patients were found to be prescribed with more than 7 drugs causing higher incidences of pDDIs. Some of the most common drug interacting pair was aspirin and clopidogrel; causing major, pharmacodynamics interaction, with a frequency of 245.The prevalence of pDDIs in the cardiology was 53.27%, and majority of the prevalence were major severity. Out of 360 cardiology patients, there were 82 interacting pairs identified during the study. Among 856 pDDIs, 256 (29.90%) were due to pharmacokinetic interactions, and 456 (53.27%) were pharmacodynamics interactions. 71 (8.29%) showing both mechanisms and 73 (8.54%) were due to unknown mechanism. Conclusion: The development of such data base in hospitals may help for the surveillance of pDDIs in hospitalized cardiac patients. The physicians should be aware of interactions among those drugs while prescribing for patients and thorough monitoring should be required for the patient safety by the implementation of admonitory guidelines and computer-based screening, which might help to prevent potentially harmful drug interactions.
